A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix, Inc.
Summary
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Description
EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor which has demonstrated antitumor activity in in vitro and in vivo models of human cancer. This Phase I open-label, multi-center, dose-escalation study will assess the safety and determine the maximum tolerated dose of EP31670 administered orally in patients with castration-resistant prostate cancer, NUT midline carcinoma and other targeted advanced solid tumors as well as chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and other targeted hematological malignancies.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Part 1 * Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen and a docetaxel-containing regimen OR * metastatic or unresectable NUT midline carcinoma for which standard curative or palliative measures do not exist; OR Part 2 * relapsed or refractory CMML following at least 4 cycles of hypomethylating agent-containing regimen or hydroxyurea unless demonstration of progression or intolerance; * advanced MF (intermediate or high-risk) following at least one JAK inhibitor-containing regimen or unsuitable candidates…
Interventions
- DrugEP31670
EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
Locations (6)
- Mayo Clinic ArizonaPhoenix, Arizona
- Mayo Clinic FloridaJacksonville, Florida
- Dana Farber Cancer InstituteBoston, Massachusetts
- Mayo Clinic RochesterRochester, Minnesota
- The University of Texas MD Anderson Cancer CenterHouston, Texas
- University of Washington/Fred Hutchinson Cancer CenterSeattle, Washington